Stephen Dodge

Dr. Dodge has over 20 years of medical affairs leadership across both small biotech and large pharma, including roles at Intercept, Merck, Novo Nordisk and Novartis. He has more than 10 years working directly in hepatology and GI, as well as metabolic disease, building out medical affairs capabilities to support market entry in new therapeutic areas across 20+ launches.